EVZIO (AUTOINJECTOR) Drug Patent Profile

Which patents cover Evzio (autoinjector), and when can generic versions of Evzio (autoinjector) launch?

Evzio (autoinjector) is a drug marketed by Kaleo Inc and is included in one NDA. There are twenty-four patents protecting this drug.

This drug has one hundred and forty-one patent family members in fifteen countries.

The generic ingredient in EVZIO (AUTOINJECTOR) is naloxone hydrochloride. There are twelve drug master file entries for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the naloxone hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Evzio (autoinjector)

A generic version of EVZIO (AUTOINJECTOR) was approved as naloxone hydrochloride by HOSPIRA on September 24^th, 1986.

Summary for EVZIO (AUTOINJECTOR)

International Patents:	141
US Patents:	24
Applicants:	1
NDAs:	1
Clinical Trials:	77
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EVZIO (AUTOINJECTOR)
DailyMed Link:	EVZIO (AUTOINJECTOR) at DailyMed

Recent Clinical Trials for EVZIO (AUTOINJECTOR)

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Nasus Pharma	PHASE1
Takeda	PHASE3
Viridian Therapeutics, Inc.	PHASE3

See all EVZIO (AUTOINJECTOR) clinical trials

US Patents and Regulatory Information for EVZIO (AUTOINJECTOR)

EVZIO (AUTOINJECTOR) is protected by twenty-four US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Kaleo Inc	EVZIO (AUTOINJECTOR)	naloxone hydrochloride	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	209862-001	Oct 19, 2016		DISCN	Yes	No			Y
Kaleo Inc	EVZIO (AUTOINJECTOR)	naloxone hydrochloride	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	209862-001	Oct 19, 2016		DISCN	Yes	No			Y
Kaleo Inc	EVZIO (AUTOINJECTOR)	naloxone hydrochloride	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	209862-001	Oct 19, 2016		DISCN	Yes	No			Y
Kaleo Inc	EVZIO (AUTOINJECTOR)	naloxone hydrochloride	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	209862-001	Oct 19, 2016		DISCN	Yes	No			Y

Expired US Patents for EVZIO (AUTOINJECTOR)

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Kaleo Inc	EVZIO (AUTOINJECTOR)	naloxone hydrochloride	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	209862-001	Oct 19, 2016
Kaleo Inc	EVZIO (AUTOINJECTOR)	naloxone hydrochloride	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	209862-001	Oct 19, 2016
Kaleo Inc	EVZIO (AUTOINJECTOR)	naloxone hydrochloride	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	209862-001	Oct 19, 2016
Kaleo Inc	EVZIO (AUTOINJECTOR)	naloxone hydrochloride	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	209862-001	Oct 19, 2016

International Patents for EVZIO (AUTOINJECTOR)

See the table below for patents covering EVZIO (AUTOINJECTOR) around the world.

Country	Patent Number	Title	Estimated Expiration
China	101087625
Japan	2008520339
Japan	2010510000
New Zealand	589864

Supplementary Protection Certificates for EVZIO (AUTOINJECTOR)

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1685839	92292	Luxembourg		PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE

Market Dynamics and Financial Trajectory for EVZIO (Autoinjector)

Last updated: July 29, 2025

---

Introduction

EVZIO, an autoinjector developed by Kaleo Pharmaceuticals (now part of Teva Pharmaceutical Industries), is primarily used for the emergency treatment of opioid overdoses through intranasal naloxone delivery. Since its FDA approval in 2016, EVZIO has played a pivotal role in addressing opioid overdose fatalities, a public health crisis intensified over recent years. It stands out as a pivotal product within the broader pharmaceutical landscape targeting overdose reversal, making its market performance and projected financial trajectory critical for understanding industry trends and investment opportunities.

---

Market Dynamics of EVZIO

Epidemiological Drivers and Public Health Needs

The escalating opioid crisis in North America, particularly the United States, has spurred rapid growth in demand for overdose reversal agents. According to the CDC, nearly 107,000 drug overdose deaths occurred in 2021, with opioids responsible for over 75% of these fatalities [1]. The pervasive nature of this crisis has prompted the U.S. government and healthcare organizations to prioritize accessible naloxone distribution, directly benefitting EVZIO's adoption.

Regulatory Environment and Policy Initiatives

Regulatory agencies, including the FDA, have facilitated easier access through policies such as standing orders that permit pharmacies and non-medical personnel to dispense naloxone. The FDA’s approval of EVZIO as a handheld, needle-free option positioned it as a user-friendly device adaptable to diverse settings—from emergency responders to community members [2].

However, recent regulatory scrutiny and legislative restrictions on drug pricing and device reimbursement processes influence market penetration and revenue streams. The Affordable Care Act and Medicaid expansion programs, which often cover emergency opioid reversal interventions, also affect market access.

Competitive Landscape and Technological Alternatives

EVZIO faces competition from generic intranasal naloxone sprays (e.g., Narcan), which are typically less expensive and have gained widespread distribution. The rapid proliferation of generic formulations has exerted downward pressure on EVZIO’s pricing, impacting its market share. Meanwhile, emerging drug delivery systems—such as auto-injectors for different medications—may influence technological preferences over time, influencing EVZIO’s market position.

Distribution and Accessibility Factors

Key factors influencing EVZIO's market dynamics include distribution channels, healthcare provider education, and community outreach programs. Since the product requires specific storage conditions and trained administration, these factors can limit broader adoption despite high demand. The COVID-19 pandemic further complicated distribution logistics, but also increased awareness around emergency preparedness.

Pricing Strategies and Reimbursement Policies

EVZIO’s premium pricing—initially around $450 per device—has been a point of contention, especially as generic competitors entered the market at significantly lower costs (~$130–$150) for comparable formulations. Reimbursement policies through Medicare and Medicaid influence affordability and, by extension, usage rates. The potential for cost-based pricing adjustments remains a critical factor in the product's long-term viability.

---

Financial Trajectory of EVZIO

Historical Revenue and Growth Trends

Initially launched in 2016, EVZIO experienced rapid uptake driven by the opioid crisis's intensification. Kaleo reported sales growth that exceeded expectations, with the product gaining approval across major healthcare channels [3]. However, the eventual introduction of generics suppressed pricing power.

Teva’s acquisition of Kaleo's assets in 2019 aimed to bolster the product’s financial performance by leveraging Teva's global footprint. Post-acquisition, financial data indicates a stabilization in sales, although growth has plateaued due to increased competition.

Profitability and Cost Factors

Brand-name EVZIO commands a premium, promising higher margins, but these margins eroded following generic market entries. Costs associated with manufacturing, distribution, and marketing, combined with R&D for new formulations, influence overall profitability. Reimbursement fluctuations directly impact net margins.

Forecasting Future Revenue Streams

Projecting EVZIO's financial trajectory entails considering:

• Market Penetration: Despite broad recognition of naloxone’s importance, market saturation may plateau due to high generic competition.
• Pricing Pressures: Price erosion from generics limits revenue growth; however, initiatives aimed at bulk procurement by government agencies sustain some top-line stability.
• Regulatory Developments: Potential FDA approvals of next-generation devices or formulations could either extend revenue streams or introduce cannibalization.

Analysts project a plateauing or slight decline in EVZIO’s market share over the next 3–5 years, unless new formulations or indications emerge. The opioid crisis’s persistence suggests baseline steady demand, though growth prematurely peaks due to commoditization.

---

Market Innovations and Strategic Opportunities

Potential avenues to revitalize EVZIO’s market share include:

• Device Advancements: Integration of smart technology—such as Bluetooth connectivity—could improve usage monitoring and adherence.
• Expansion of Indications: Investigating EVZIO's application in other emergencies or expanding to other nasal or auto-injector medications.
• Global Market Expansion: Emerging markets with rising opioid misuse may present growth opportunities, provided regulatory and pricing barriers are managed.

---

Legal and Ethical Considerations

Although EVZIO is a life-saving device, patent disputes and pricing controversies continue to influence its market environment. Teva's commitment to affordable access, especially in underserved communities, remains paramount; failure to do so could prompt policy interventions and impact financial projections adversely.

---

Conclusion

EVZIO's market dynamics are shaped by a combination of acute public health needs, regulatory factors, competitive pressures, and technological innovation. The initial rapid growth driven by the opioid epidemic is materializing into a mature phase characterized by stabilization, cost competition, and market saturation. Financially, the product’s future depends on strategic positioning amid rising generic competition, potential new indications, and technological evolution.

---

Key Takeaways

• The ongoing opioid overdose crisis sustains demand for naloxone autoinjectors like EVZIO, ensuring a baseline revenue stream despite market saturation.
• Competitive pricing with generics remains a critical challenge, pressuring profit margins and influencing market share.
• Regulatory support for naloxone accessibility enhances EVZIO’s distribution but also invites scrutiny over costs and reimbursement policies.
• Innovation in device design and potential expanded indications offer growth opportunities, though broader market penetration remains limited by price and accessibility barriers.
• Long-term financial success hinges on strategic adaptation to market conditions, including cost management, technological enhancement, and expansion into new geographical or clinical segments.

---

FAQs

1. How does EVZIO differentiate from generic naloxone formulations?
EVZIO offers a user-friendly, needle-free nasal autoinjector designed for ease of use in emergency settings, providing a potentially more intuitive administration method compared to traditional nasal sprays. However, it faces significant price competition from generics, which are typically more affordable.

2. What regulatory hurdles affect EVZIO’s market expansion?
Regulatory challenges include obtaining approval for new indications, compliance with evolving safety standards, and navigating reimbursement policies that can limit accessibility, especially in lower-income communities.

3. How does pricing impact EVZIO’s market share?
High pricing limits adoption, particularly because many payers favor lower-cost generic alternatives. Reimbursement structures and government procurement programs are pivotal in determining market penetration.

4. What is the potential for EVZIO in international markets?
Emerging markets with increasing opioid misuse represent untapped opportunities, although regulatory approvals, distribution infrastructure, and affordability will impact market entry strategies.

5. Are there innovations on the horizon that could affect EVZIO’s market?
Yes, developments such as smart auto-injectors, devices with digital monitoring, and expanded therapeutic indications could transform EVZIO’s positioning, contingent on regulatory approval and consumer acceptance.

---

Sources:

1. Centers for Disease Control and Prevention (CDC). 2021 Overdose Statistics. [Online] Available at: [CDC website]
2. U.S. Food and Drug Administration (FDA). FDA Approvals and Guidance on Naloxone Devices. [Online]
3. Kaleo Pharmaceuticals’ Official Reports and Teva Annual Financial Statements.